1SADLEX J E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura[J]. Blood, 2008,112:11-18.
2SADLER J E. Thrombotic thrombocytopenic purpura: a moving target [J]. Hematology Am Soc Hematol Educ Program,2006:415-420.
3TSAI H M, LIAN E C. Antibodies to yon Willeband factor-cleaving protease in acute thrombotic thrombo- cytopenic purprua[J]. N Engl J Med, 1998,339 : 1585 -1594.
9KELLY F E,TREACHER D F,WILLIAMS F M,et al. Coma in thrombotic thrombocytopenic purpura[J]. J Neurol Neurosurg Psychiatry, 1999,66 : 689- 690.
10BARON Y, BARGEMANN T, HARTEN P, et al. Thrombocytopenic thrombotic purpura: severe clinic with no CT,minor MRI, but a SPECT correlate[J].Eur J Radiol,1999,31:56-62.
4MOAK J L. Thrombotic Microangiopathies [J]. N Engl J Med, 2002, 347: 589-600.
5ALLFORD SL, HUNT BL ROSE P, et al. Guidelines on the diagnosis and man agement of thrombotic microangiopathic haemolytic anaemias[J]. BrJ Haematol, 2003, 120: 556-556.
7Iwai H, Nagaki M, Naito T, et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med, 1998,26 (5) :873-876.
8Rock G. The management of thrombotic thrombocytopenic purpura in 2005. Semi Thromb Hemost, 2005, 31 ( 6 ) : 709-716.
9Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol, 2004, 124 (fi): 787-795.
10Tsai H M, Raoufi M ,Zhou W ,et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura[ J]. Thromb Haemost ,2006,95 (4) :886-892.
1Terrell DR, Williams LA, Vesely SK, et al. The inci- dence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005 (3): 1432-1436.
2George JN. The thrombotic thrombocytopenie purpura and hemolytic uremic syndromes: overview of pathogen-esis (Experience of The Oklahoma TYP-HUS Registry, 1989-2007). Kidney Int Suppl, 2009 (112): $8-S10.
3Porta C, Caporali R, Montecucco C. Thrombotic throm- bocytopenic purpura and autoimmunity: a tale of shad- ows and suspects. Haematologica, 1999 (84): 260-269.
4Druschky A, Erbguth F, Strauss R, et al. Central ner- vous system involvement in thrombotic thrombocytopenic purpura. Eur Neurol, 1998 (40): 220-224.
5Giovanna Meloni, Anna Prola, Giovanni Antonini, et al. Thrombotic thrombocytopenic purpura: prospective neu- rologic, neuroimaging and neurophysiologic evaluation. Haematologica, 2001 (86): 1194-1199.
6Burrus TM, Wijdicks EF, Rabinstein AA. Brain lesions are most often reversible in acute thrombotic thrombo- cytopenic purpura. Neurology, 2009, 73 (1): 66-70.
7Lapp H, Shin D I, KroeHs W, et al. Cardiogenic shock due to thrombotic thrombocytopenic purpura. Z Kardiol, 2004, 93 (6): 486-492.
8Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine, 1966 (45): 139-159.
9Rock GA, Shumak KH, Buskard NA, et al. Compari- son of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med, 1991 (325): 393-397.
